Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab for Fibromyalgia
NCT03965091Phase 2Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2019
- Primary completion
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of fremanezumab in fibromyalgia (FM), sponsored by Teva Pharmaceutical Industries Ltd.. Started Jul 2019; status: terminated.
02
Drugs
fremanezumab
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT03965091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03965091.